Search

Displaying results 3621 - 3630 of 10000 in total
  1. Drug

    Cod liver oil

    go.drugbank.com/drugs/DB11321
    ApprovedNutraceuticalVet approved

    Also being a rich source of vitamin A and D, cod liver oil can be taken orally as daily supplements. … It is used as an adjunct treatment and preventative therapy of rickets, osteomalacia and osteoporosis while meeting the consumption criteria.

  2. Drug

    Satavaptan

    go.drugbank.com/drugs/DB14923
    Investigational

    Satavaptan is under investigation in clinical trial NCT00359437 (Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver).

  3. Drug

    Pardoprunox

    go.drugbank.com/drugs/DB12061
    Investigational

    Pardoprunox is a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist properties. … Pardoprunox has been used in trials studying the treatment of Early Stage Parkinson's Disease and Advanced Stage Parkinson's Disease.

  4. Drug

    Cyamemazine

    go.drugbank.com/drugs/DB09000
    Experimental

    Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A). … Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety.

  5. Drug

    Zastaprazan

    go.drugbank.com/drugs/DB21524
    Investigational

    Zastaprazan has a monoisotopic molecular weight of 362.21 Da. … The usage of the INN stem '-prazan' in the name indicates that Zastaprazan is a proton pump inhibitor, not dependent on acid activation.

  6. Drug

    Linaprazan

    go.drugbank.com/drugs/DB20602
    Investigational

    Linaprazan has a monoisotopic molecular weight of 366.21 Da. … The usage of the INN stem '-prazan' in the name indicates that Linaprazan is a proton pump inhibitor, not dependent on acid activation.

  7. Drug

    Tocilizumab

    go.drugbank.com/drugs/DB06273
    ApprovedInvestigational

    [L12789] It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. … [L12789] It was later approved by Health Canada on 30 April 2010.

    Products: ACTEMRA (162 MG SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE), ACTEMRA 162MG/0.9ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
  8. Drug

    Drotaverine

    go.drugbank.com/drugs/DB06751
    ApprovedWithdrawn

    Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4). … It is approved for use in Thailand as oral tablets or intramuscular injections.[L22689]

  9. Drug

    Silanol

    go.drugbank.com/drugs/DB11343
    Approved

    Silanol is an FDA-approved food contact substance that is commonly used in organosilicon chemistry and silicate mineralogy.

  10. Drug

    Alclometasone

    go.drugbank.com/drugs/DB00240
    Approved

    Alclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent.